Singapore, July 18 -- Japan-headquartered Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximatelyJPY 1 billion($7.3 million) in four R&D projects for the development of vaccine, drug, and diagnostics for malaria and tuberculosis (TB).

GHIT Fund has decided to investJPY 800 million($5.5 million) in a malaria vaccine development project currently in the preclinical stage. This project is being led by the European Vaccine Initiative, the Research Institute for Microbial Diseases (RIMD) atOsakaUniversity, theUniversity of Copenhagen, the University of Tubingen, Danish biotechnology company AdaptVac, Ajinomoto Co., Inc., and Nobelpharma Co., Ltd.

This investment is a continuation of previous projects...